Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1252W HIGH $0.77
Volume
2.27 M
Value Traded
211.20 K
Short % Float
7.64%
-3.11%Week
-29.07%1 Month
-60.87%3 Month
-67.41%6 Month
-98.42%5 Year
-98.82%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
73.58 M
EPS (TTM)
-0.44
P/E Ratio
-
Ent. Value
79.42 M
Total Shares
336.39 M
Float Shares
324.28 M
Insiders
2.15%
Institutions
15.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
SGMO Catalyst Timeline
Dated clinical, regulatory and corporate events for Sangamo Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How SGMO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-05-12 | ST-503 | Pre-clinical data readout | Pre-clinical |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$60M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
0.8x
rNPV / MCap
Sangamo Therapeutics, Inc. faces pipeline headwinds (39/100), with $4.5B risk-adjusted pipeline value, led by SB-509 in Diabetes Mellitus, Type 1 (Phase 2), across $114B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SB-509 Small moleculeCompletedNCT01079325 | Diabetes Mellitus, Type 1 | Phase 2 | COMPLETED | 394 | Apr 1, 2016 |
Clinical Trial Results
Readouts, endpoints and source filings for every SGMO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| isaralgagene civaparvovec | Fabry disease | Phase 1/2 | 2026-02-04 | mean annualized e GFR slope: 1.965 mL/min/1.73m2/year; confidence interval: -0.153, 4.083; mean annualized e GFR slope 104 weeks: 1.747 mL/min/1.73m2/year; confidence interval 104 weeks: -0.106, 3.601Read More | Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Davis Gregory DOfficer (Head of Research & Technology) | Sell | -69,827 115,284 held | $0.25 | 04/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SGMO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 300.00 K | 1.22 M |
SGMO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SGMO ranks across every disease it competes in
Competitive Position is a premium feature
See how SGMO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSGMO News
About Sangamo Therapeutics, Inc.
Headquarters501 CANAL BLVD., RICHMOND, CA, 94084
BIOPHARMAWATCH ELITE PLUS
Trade the next SGMO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime